Form 4: BioCardia Director Simon Stertzer Boosts Stake with Significant Private Placement Purchase

BioCardia, Inc. Director Simon H. Stertzer acquired 72,289 shares of common stock and an equal number of warrants through a private placement, significantly increasing his beneficial ownership.

Summary

• Director Simon H. Stertzer participated in a private placement on June 30, 2025, acquiring additional securities in BioCardia, Inc.
• He purchased 72,289 shares of BioCardia, Inc. common stock at a price of $2.075 per share.
• Concurrently, he received 72,289 warrants, each exercisable for one share of common stock at an exercise price of $1.95, with an expiration date of June 30, 2030.
• This transaction was part of a private placement that included qualified institutional buyers and institutional accredited investors.
• Following this acquisition, Mr. Stertzer's beneficial ownership includes 57,138 direct common shares and 258,745 indirect common shares, totaling 315,875 common shares.
• His beneficial ownership also includes 177,275 indirect warrants.

Sentiment

Score: 8

Explanation: A high score due to significant insider buying, which typically signals strong confidence from management in the company's future prospects and valuation. The participation in a private placement alongside institutional investors further reinforces this positive sentiment.

Positives

• Significant insider buying by a Director, indicating strong confidence in the company's future prospects and valuation.
• Participation in a private placement alongside institutional investors suggests a broader vote of confidence from sophisticated market participants.
• The warrant exercise price of $1.95 is slightly below the common stock purchase price of $2.075, offering potential upside leverage.

Future Outlook

The document does not provide forward-looking statements or guidance beyond the expiration date of the warrants.

Management Comments

• The document is a transactional filing and does not contain direct management quotes or statements.

Industry Context

This Form 4 filing reflects an insider's investment decision within the biotechnology or medical device industry, specifically for a company focused on cardiac therapies. Insider buying can signal management's confidence in the company's prospects, which is a common indicator observed across various industries.

Related Party Transactions

• The reporting person, a director, participated in a private placement with the issuer, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the director's significant investment as a positive signal, potentially increasing investor confidence and demand for the stock.

Key Dates

Recommendation

Keywords

BioCardia, BCDA, Simon Stertzer, Insider Buying, Form 4, Private Placement, Common Stock, Warrants, Director, Beneficial Ownership